In immunocompetent tumor models, FSTL3 knockout led to an increased proportion of CD8+ T cells and a reduction in regulatory T cells and exhausted T cells, improving the efficacy of anti-PD1 therapy [21]. The gene discussed is CD8A; the disease is neoplasm.